I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Biostage (BSTG) Breech, breech … breech

October 6, 2017

BSTG has been delisted from NASDAQ effective 10/6/17 to trade on the OTCQB, Pecos investment is in the wind and that ain’t all, what a MESS! Another nail in its cross of demise as CMO and President resigns while the company seeks any alternative ...  

Juno Therapeutics (JUNO) proposes $225 M follow-on offering

September 20, 2017

Shares closed up +$1.41 or +3.22 to $45.21 while the aftermarket drops -$1.95 or -4.31% 106,32 M shares outstanding a float of 70.66 M and a BIG shirt position of 15.43 M shares and 697.62 M in cash, 10 M indebtbut 82,57 M in revenue

VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached

August 31, 2017

VTGN is down -$0.10 or -5.50% to $1.72 ​A little heavy on the warrants to raise $2.4 million ...?  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.